Aton Ra Partners Nurix Therapeutics, Inc. Transaction History

Aton Ra Partners

$50.1 Million
Q4 2023

A detailed history of Aton Ra Partners transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Aton Ra Partners holds 21,102 shares of NRIX stock, worth $216,084. This represents 0.43% of its overall portfolio holdings.

Number of Shares

21,102

Previous 24,227 12.9%

Holding current value

$216,084

Previous $190,000 14.21%

% of portfolio

0.43%

Previous 0.4%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$4.25 - $10.71 $13,281 - $33,468	-3,125 Reduced 12.9%	21,102 $217,000
Q3 2023 Oct 25, 2023	SELL	$7.86 - $10.08 $46,491 - $59,623	-5,915 Reduced 19.62%	24,227 $190,000
Q2 2023 Jul 18, 2023	SELL	$8.7 - $13.28 $24,290 - $37,077	-2,792 Reduced 8.48%	30,142 $301,000
Q1 2023 May 05, 2023	SELL	$8.56 - $13.26 $34,188 - $52,960	-3,994 Reduced 10.82%	32,934 $292,000
Q4 2022 Feb 02, 2023	SELL	$9.86 - $14.59 $98,471 - $145,710	-9,987 Reduced 21.29%	36,928 $405,000
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $28,383 - $45,602	-2,302 Reduced 4.68%	46,915 $611,000
Q2 2022 Aug 15, 2022	BUY	$7.88 - $14.82 $13,813 - $25,979	1,753 Added 3.69%	49,217 $624,000
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $2,225 - $5,099	172 Added 0.36%	47,464 $665,000
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $187,124 - $244,260	7,080 Added 17.61%	47,292 $1.37 Million
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $377,008 - $609,090	16,601 Added 70.31%	40,212 $1.21 Million
Q2 2021 Aug 12, 2021	BUY	$24.21 - $35.89 $571,622 - $847,398	23,611 New	23,611 $626,000

Others Institutions Holding NRIX

# of Institutions

185

Shares Held

67M

Call Options Held

318K

Put Options Held

42.4K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $483M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.

Account